Difference between revisions of "GUILLAIN BARRE SYNDROME (GBS)-POOR PROGNOSIS"
(Imported from text file) |
|||
| Line 10: | Line 10: | ||
<br/>6. Severe disease at presentation | <br/>6. Severe disease at presentation | ||
<br/>7. Campylobacter jejuni infection | <br/>7. Campylobacter jejuni infection | ||
<br/> | |||
<br/>8. Patients showing no improvement at 3 weeks of plateau of disease | <br/>8. Patients showing no improvement at 3 weeks of plateau of disease | ||
<br/> | <br/> | ||
Latest revision as of 10:34, 21 February 2023
SUMMARY
PATIENT FACTORS
1. Older age (> 50 years)
DISEASE FACTORS
2. Subgroup of GBS with primary axonal degeneration
3. Rapid onset
4. Progression to quadriplegia
5. Respiratory dependence
6. Severe disease at presentation
7. Campylobacter jejuni infection
8. Patients showing no improvement at 3 weeks of plateau of disease
TREATMENT FACTORS
9. Requirement for respiratory support
10. Abnormal peripheral nerve function
11. No plasmapheresis is performed
Reference(s)
Hallum A. Neuromuscular diseases. In: Neurological Rehabilitation. Umphred DA, ed. 4th edn. St Louis: Mosby, 2001;363–415.
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
